Cingulate Q1 net loss widens to $9.3M; cash at $25.9M; CTx-1301 PDUFA May 31

Cingulate Inc.

Net loss of $9.3M for Q1 2026, up from $3.9M a year ago; G&A expenses surged to $5.7M on commercial build-out.
Cash and cash equivalents $25.9M at Mar 31, up $14.9M from Dec 31, extending runway into 2027.
FDA review of CTx-1301 NDA ongoing; PDUFA target action date remains May 31, 2026.
Commercial readiness advanced with AI-driven tools and IQVIA sales force agreement for potential launch.
R&D expenses decreased 1.8% to $2.2M as clinical studies concluded, partly offset by regulatory and CMC activities.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.